Idiopathic pulmonary fibrosis (IPF) is one of the most challenging diseases for chest physicians for a number of reasons, including the complexity of the diagnostic process, which requires close interaction with different specialists, and the almost invariably poor prognosis, with a 5-year survival of ∼20%. Moreover, until recently, IPF has lacked effective therapies. Following two decades of clinical trials, most of which have produced negative results, pirfenidone, a compound with broad antifibrotic, antiinflammatory, and antioxidant properties, and nintedanib, an orally available, small molecule tyrosine kinase inhibitor with selectivity for vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), and fibroblast growth factor (FGF) receptors, have proved equally effective in slowing down functional decline and disease progression with an acceptable safety profile. However, neither pirfenidone nor nintedanib is a cure for IPF;neither drug improves lung function and the disease continues to progress in most patients despite treatment. Likewise, the modalities for the follow-up of IPF patients are poorly defined. Accordingly, all decisions related to patient management need to be extensively discussed and agreed upon with the patients and their families. As a result, few respiratory disorders require ofchest physicians more interactive skills and more dedication than IPF.

Management of Idiopathic Pulmonary Fibrosis / Cerri, Stefania; Spagnolo, Paolo; Luppi, Fabrizio; Sgalla, Giacomo; Richeldi, Luca. - (2018), pp. 55-63. [10.1016/B978-0-323-48024-6.00004-5]

Management of Idiopathic Pulmonary Fibrosis

CERRI, Stefania;SPAGNOLO, Paolo;LUPPI, Fabrizio;SGALLA, Giacomo;RICHELDI, Luca
2018

Abstract

Idiopathic pulmonary fibrosis (IPF) is one of the most challenging diseases for chest physicians for a number of reasons, including the complexity of the diagnostic process, which requires close interaction with different specialists, and the almost invariably poor prognosis, with a 5-year survival of ∼20%. Moreover, until recently, IPF has lacked effective therapies. Following two decades of clinical trials, most of which have produced negative results, pirfenidone, a compound with broad antifibrotic, antiinflammatory, and antioxidant properties, and nintedanib, an orally available, small molecule tyrosine kinase inhibitor with selectivity for vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), and fibroblast growth factor (FGF) receptors, have proved equally effective in slowing down functional decline and disease progression with an acceptable safety profile. However, neither pirfenidone nor nintedanib is a cure for IPF;neither drug improves lung function and the disease continues to progress in most patients despite treatment. Likewise, the modalities for the follow-up of IPF patients are poorly defined. Accordingly, all decisions related to patient management need to be extensively discussed and agreed upon with the patients and their families. As a result, few respiratory disorders require ofchest physicians more interactive skills and more dedication than IPF.
2018
19-mag-2017
Interstitial Lung Disease
Collard, Harold R; Richeldi, Luca
9780323480246
Elsevier
Management of Idiopathic Pulmonary Fibrosis / Cerri, Stefania; Spagnolo, Paolo; Luppi, Fabrizio; Sgalla, Giacomo; Richeldi, Luca. - (2018), pp. 55-63. [10.1016/B978-0-323-48024-6.00004-5]
Cerri, Stefania; Spagnolo, Paolo; Luppi, Fabrizio; Sgalla, Giacomo; Richeldi, Luca
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1137839
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact